Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation

@article{Khn2012AdipocytesecretedFI,
  title={Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation},
  author={Markus C. K{\"u}hn and Holger Sven Willenberg and Matthias Schott and Claudia Papewalis and Ulla Stumpf and Sascha Flohe and Werner A. Scherbaum and Sven Schinner},
  journal={Molecular and Cellular Endocrinology},
  year={2012},
  volume={349},
  pages={180-188}
}
View on Elsevier
doi.org
57 Citations
Highly Influential Citations
1
Background Citations
20

Figures from this paper

57 Citations

Interleukin 6 and/or Interleukin 17A Modulate the OPG/RANKL System of MC3T3-E1 Murine Osteoblast Cell Line
TLDR
Findings suggest a new mechanism of regulation by these cytokines on the expression of OPG and RANKL, which could promote osteogenesis and diminish osteoclastogenesis.
The Importance of the Prenyl Group in the Activities of Osthole in Enhancing Bone Formation and Inhibiting Bone Resorption In Vitro
TLDR
It is found that osthole exerted a potent ability to promote proliferation and osteogenic function of rat bone marrow stromal cells and osteoblasts, and the prenyl group plays an important role in these bone-protective effects.
Dioscin promotes osteoblastic proliferation and differentiation via Lrp5 and ER pathway in mouse and human osteoblast-like cell lines
TLDR
The current study is the first to reveal that dioscin can promote osteoblasts proliferation and differentiation via Lrp5 and ER pathway.
Osteoblasts subjected to tensile force induce osteoclastic differentiation of murine macrophages in a coculture system
The PPAR-γ antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice
TLDR
It is demonstrated that T007 impedes osteoclastogenesis and will be useful for the therapy of bone related diseases, essentially osteoporosis.
Intercellular Cross-Talk Among Bone Cells: New Factors and Pathways
TLDR
Recent work that provides new insights into some of the communication networks and the factors involved are discussed, including osteocytic production of receptor activator of nuclear factor-κB ligand and sclerostin, osteoblastic production of interleukin-33, osteoclast-derived Semaphorin 4D, ephrin signaling, and signals from T helper cells and resident osteal macrophages.
Fibroblast growth factor 2 exacerbates inflammation in adipocytes through NLRP3 inflammasome activation.
TLDR
FGF2 is an adipokine that may exacerbate the inflammatory response in adipocytes through NLRP3 inflammasome activation, which is suggested to be a major risk factor for the development of obesity-induced insulin resistance.
Treatment with an inhibitor of fatty acid synthase attenuates bone loss in ovariectomized mice.
Preventive Effects of Chrysanthemum coronarium L. Extract on Bone Metabolism In Vitro and In Vivo
TLDR
Investigating the antiosteoporotic effects of CC extracts in in vitro cell cultures and in vivo bone loss animal models suggests that CC extract may be considered as a natural therapeutic or preventive agent for osteoporosis.
Effects of Scytosiphon lomentaria on osteoblastic proliferation and differentiation of MC3T3-E1 cells
TLDR
Treatment of Scytosiphon lomentaria extract is demonstrated to promote differentiation inducement and proliferation of osteoblasts and, therefore, may help to elucidate the transcriptional mechanism of bone formation and possibly lead to the development of bone-forming drugs.
...
...

References

SHOWING 1-10 OF 57 REFERENCES
Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro
TLDR
The presence of FA within the marrow milieu can contribute to the age‐related changes in bone mass and can be prevented by the inhibition of FA synthase.
Regulation of Osteoblast, Chondrocyte, and Osteoclast Functions by Fibroblast Growth Factor (FGF)-18 in Comparison with FGF-2 and FGF-10*
TLDR
FGF-18 may compensate for the action of FGF-2 on bone and cartilage and not only induced osteoclast formation through receptor activator of nuclear factor-κB ligand and cyclooxygenase-2 but also stimulated osteOClast function to form resorbed pits on a dentine slice in the mouse coculture system.
IL-6 receptor expression and IL-6 effects change during osteoblast differentiation.
Marrow adipocytes regulate growth and differentiation of osteoblasts.
TLDR
Exposure of MBA-15 cells to known growth factors: BMP-2, TGF beta, IGF-I and PDGF or combined with 14F1.1 CM resulted in a dominant effect of the latter, which may imply that marrow adipocytes produce factor/s that participate in the stromal regulation of osteoblastic functions.
The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts
TLDR
The data suggest that Runx2 and the FGF/proteoglycan axis may form an extracellular matrix (ECM)‐related regulatory feed‐back loop that controls osteoblast proliferation and execution of the osteogenic program.
Influence of mature adipocytes on osteoblast proliferation in human primary cocultures.
Fibroblast growth factor 2 induced proliferation in osteoblasts and bone marrow stromal cells: a whole cell model.
TLDR
A whole-cell kinetic model relating receptor-mediated binding, internalization, and processing of FGF2 to osteoblastic proliferative response is presented and evidence of potential multistep processes involved in heparan-sulfate proteoglycans-bound F GF2 release, internalized, and fragment formation in conjunction with the normal metabolism of the proteoglycan is shown.
Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation.
bFGF Administration Lowers the Phosphate Threshold for Mineralization in Bone Marrow Stromal Cells
TLDR
Results show that in vitro administration of bFGF accelerates the calcification process and lowers the phosphate threshold needed for successful bone nodule formation, and indicate that the delay in mineralization observed in vivo may not be caused by decreased phosphate availability alone.
Anti‐apoptotic Bcl‐2 enhancing requires FGF‐2/FGF receptor 1 binding in mouse osteoblasts
TLDR
A novel mechanism in which PGF2α induces FGF‐2 binding to its specific cell surface receptor 1 leading to a cascade pathway that culminates with increased mouse osteoblast survival is reported.
...
...